JawaPos.com – Until now, a vaccine to increase human immunity against Dengue Hemorrhagic Fever (DHF) has not been found. Even so researchers continue to try to find vaccine candidates. This is especially important for countries that are subscribed to dengue fever such as Indonesia.
The pharmaceutical company Takeda Pharmaceutical Company Limited (Takeda) submitted a regulatory filing for the dengue hemorrhagic fever vaccine (TAK-003) to the European pharmaceutical agency, the European Medicines Agency (EMA). Takeda’s Vice President and Global Dengue Program Head, Derek Wallace, said the TAK-003 vaccine candidate was being studied for the prevention of dengue hemorrhagic fever (DHF) caused by viral serotypes in individuals aged 4 to 60 years. He added that Takeda also intends to submit regulatory filings in Indonesia, Argentina, Brazil, Colombia, Malaysia, Mexico, Singapore, Sri Lanka and Thailand in 2021.
“The submission of the proposed TAK-003 DBD vaccine candidate regulations marks an important development for people who live or travel to various communities burdened by the threat of dengue hemorrhagic fever,” Wallace said in a press release on Sunday (28/3).
Also Read: DHF Cases Can Decrease Up to 77 Percent Thanks to Wolbachia Bacteria
Wallace continued, the dengue epidemic which kills half a million people around the world each year can overwhelm governments and communities because of its huge impact on the health care system. In Indonesia alone, cases of dengue hemorrhagic fever in 2020 reached 95,893 people with the number of deaths due to dengue fever as many as 661 people. According to Wallace, with the limited options available to prevent the disease, there is an urgent need for a dengue vaccine.
“We are committed to working with relevant regulatory authorities as well as recommendation agencies to support the evaluation of the delivery of our regulations and gain access to the TAK-003 vaccine,” he said.
–
Editor: Nurul Adriyana Salbiah
Reporter: Marieska Harya Virdhani
– .
